The utility of nutritional supportive care with an eicosapentaenoic acid (EPA)-enriched nutrition agent during pre-operative chemoradiotherapy for pancreatic cancer: Prospective randomized control study.


Journal

Clinical nutrition ESPEN
ISSN: 2405-4577
Titre abrégé: Clin Nutr ESPEN
Pays: England
ID NLM: 101654592

Informations de publication

Date de publication:
10 2019
Historique:
received: 18 06 2018
revised: 10 03 2019
accepted: 03 06 2019
entrez: 28 8 2019
pubmed: 28 8 2019
medline: 25 8 2020
Statut: ppublish

Résumé

Neoadjuvant chemoradiotherapy (NACRT) for pancreatic cancer (PC) is potentially associated with various toxicities, which can lead to impaired nutritional status. Eicosapentaenoic acid (EPA) can reduce proinflammatory cytokines and positively influence cancer cachexia syndrome. The aim of this study is to clarify the utility of EPA enriched nutrition support during NACRT for PC. We randomly assigned 62 patients with PC that received NACRT to either a nutrition intervention (NI) or a normal diet (ND). Patients in the NI group received 2 bottles/day (550 kcal/day) of an EPA-enriched nutrition supplement during NACRT. The primary endpoints were the before-to-after NACRT ratios (post/pre ratios) of skeletal muscle mass and psoas major muscle area (PMA). The secondary endpoints were the post/pre ratios of other nutritional parameters and treatment-related toxicities. Only 14 patients (45.2%) in the NI group consumed more than 50% of the EPA-enriched supplement provided. The post/pre ratio of skeletal muscle mass in the NI group (0.99 ± 0.060) was not significantly different from that of the ND group (0.96 ± 0.079, p = 0.102). However, patients that consumed ≥50% of the EPA-enriched supplement (the good intake group) had significantly higher skeletal muscle mass ratios than patients in the ND group (p = 0.042). The PMA ratio was significantly higher in the NI group (0.96 ± 0.081) than in the ND group (0.89 ± 0.072, p = 0.001). The NI and ND groups were not significantly different in other nutritional parameters or in NACRT-related toxicity. We found that EPA-enriched intake could potentially improve the nutritional status of patients with PC that received NACRT, but it was difficult for many patients to drink, due to its disagreeable taste. University Hospital Medical Information Network (http://www.umin.ac.jp), registration number UMIN000033589, https://upload.umin.ac.jp/cgi-bin/ctr_e/ctr_view.cgi?recptno=R000038300.

Sections du résumé

BACKGROUND & AIMS
Neoadjuvant chemoradiotherapy (NACRT) for pancreatic cancer (PC) is potentially associated with various toxicities, which can lead to impaired nutritional status. Eicosapentaenoic acid (EPA) can reduce proinflammatory cytokines and positively influence cancer cachexia syndrome. The aim of this study is to clarify the utility of EPA enriched nutrition support during NACRT for PC.
METHODS
We randomly assigned 62 patients with PC that received NACRT to either a nutrition intervention (NI) or a normal diet (ND). Patients in the NI group received 2 bottles/day (550 kcal/day) of an EPA-enriched nutrition supplement during NACRT. The primary endpoints were the before-to-after NACRT ratios (post/pre ratios) of skeletal muscle mass and psoas major muscle area (PMA). The secondary endpoints were the post/pre ratios of other nutritional parameters and treatment-related toxicities.
RESULTS
Only 14 patients (45.2%) in the NI group consumed more than 50% of the EPA-enriched supplement provided. The post/pre ratio of skeletal muscle mass in the NI group (0.99 ± 0.060) was not significantly different from that of the ND group (0.96 ± 0.079, p = 0.102). However, patients that consumed ≥50% of the EPA-enriched supplement (the good intake group) had significantly higher skeletal muscle mass ratios than patients in the ND group (p = 0.042). The PMA ratio was significantly higher in the NI group (0.96 ± 0.081) than in the ND group (0.89 ± 0.072, p = 0.001). The NI and ND groups were not significantly different in other nutritional parameters or in NACRT-related toxicity.
CONCLUSIONS
We found that EPA-enriched intake could potentially improve the nutritional status of patients with PC that received NACRT, but it was difficult for many patients to drink, due to its disagreeable taste. University Hospital Medical Information Network (http://www.umin.ac.jp), registration number UMIN000033589, https://upload.umin.ac.jp/cgi-bin/ctr_e/ctr_view.cgi?recptno=R000038300.

Identifiants

pubmed: 31451252
pii: S2405-4577(18)30354-1
doi: 10.1016/j.clnesp.2019.06.003
pii:
doi:

Substances chimiques

eicosapentaenoic acid ethyl ester 6GC8A4PAYH
Eicosapentaenoic Acid AAN7QOV9EA

Banques de données

JPRN
['UMIN000033589']

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

148-153

Informations de copyright

Copyright © 2019 European Society for Clinical Nutrition and Metabolism. Published by Elsevier Ltd. All rights reserved.

Auteurs

Hirofumi Akita (H)

Department of Surgery, Osaka International Cancer Institute, Japan; Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Japan. Electronic address: hirofumiakita@hotmail.com.

Hidenori Takahashi (H)

Department of Surgery, Osaka International Cancer Institute, Japan.

Kei Asukai (K)

Department of Surgery, Osaka International Cancer Institute, Japan.

Akira Tomokuni (A)

Department of Surgery, Osaka International Cancer Institute, Japan.

Hiroshi Wada (H)

Department of Surgery, Osaka International Cancer Institute, Japan.

Satoko Marukawa (S)

Department of Endocrinology and Metabolism, Osaka International Cancer Institute, Japan.

Tomoyuki Yamasaki (T)

Department of Endocrinology and Metabolism, Osaka International Cancer Institute, Japan.

Yoshitomo Yanagimoto (Y)

Department of Surgery, Osaka International Cancer Institute, Japan.

Yusuke Takahashi (Y)

Department of Surgery, Osaka International Cancer Institute, Japan.

Keijiro Sugimura (K)

Department of Surgery, Osaka International Cancer Institute, Japan.

Kazuyoshi Yamamoto (K)

Department of Surgery, Osaka International Cancer Institute, Japan.

Junichi Nishimura (J)

Department of Surgery, Osaka International Cancer Institute, Japan.

Masayoshi Yasui (M)

Department of Surgery, Osaka International Cancer Institute, Japan.

Takeshi Omori (T)

Department of Surgery, Osaka International Cancer Institute, Japan.

Hiroshi Miyata (H)

Department of Surgery, Osaka International Cancer Institute, Japan.

Ayami Ochi (A)

Department of Nursing, Osaka International Cancer Institute, Japan.

Ayano Kagawa (A)

Department of Nursing, Osaka International Cancer Institute, Japan.

Yuko Soh (Y)

Department of Nutrition, Osaka International Cancer Institute, Japan.

Yuko Taniguchi (Y)

Department of Nutrition, Osaka International Cancer Institute, Japan.

Masayuki Ohue (M)

Department of Surgery, Osaka International Cancer Institute, Japan.

Masahiko Yano (M)

Department of Surgery, Osaka International Cancer Institute, Japan.

Masato Sakon (M)

Department of Surgery, Osaka International Cancer Institute, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH